Detalhe da pesquisa
1.
Detailed Long-term Dynamics of Neutrophil-to-Lymphocyte Ratio under Biologic Treatment Reveals Differential Effects of Tumour Necrosis Factor-alpha and Interleukin 12/23 Antagonists.
Acta Derm Venereol
; 101(10): adv00568, 2021 09 30.
Artigo
Inglês
| MEDLINE | ID: mdl-34590148
2.
Evaluation of Psoriasis Area and Severity Index as a Proxy for Bio-markers of Systemic Disease under Treatment with Tumour Necrosis Factor-alpha and Interleukin 12/23 Antagonists in Patients with Psoriasis: A Retrospective Cohort Study of 186 Treatment Cycles.
Acta Derm Venereol
; 101(5): adv00462, 2021 May 25.
Artigo
Inglês
| MEDLINE | ID: mdl-33903917
3.
Routine Laboratory Parameter Dynamics and Laboratory Adverse Events in Psoriasis Patients on Long-term Treatment with Adalimumab, Etanercept, and Ustekinumab.
Acta Derm Venereol
; 97(6): 705-710, 2017 Jun 09.
Artigo
Inglês
| MEDLINE | ID: mdl-28224166
4.
Long-term safety of combination treatment with methotrexate and tumor necrosis factor (TNF)-α antagonists versus TNF-α antagonists alone in psoriatic patients.
J Dermatol
; 48(6): 835-843, 2021 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-33470023
5.
Baseline anti-dsDNA concentrations and previous treatments predict response to Adalimumab and Etanercept: a retrospective investigation of 146 psoriasis patients.
J Dermatol Sci
; 76(3): 180-5, 2014 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-25306295